Soleno Therapeutics (SLNO) Free Cash Flow (2013 - 2026)
Soleno Therapeutics (SLNO) posted quarterly Free Cash Flow of $26.0 million for Q1 2026, up 179.31% year-over-year from $9.3 million in Q1 2025, and down 46.6% quarter-over-quarter from $48.6 million in Q4 2025.
Soleno Therapeutics (SLNO) Free Cash Flow (2013 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Free Cash Flow for 14 consecutive years, with $26.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 179.31% year-over-year to $26.0 million; the TTM figure through Mar 2026 stood at $105.5 million (up 217.79% YoY), while the FY2025 annual figure was $46.7 million, up 167.41% from the prior year.
- Free Cash Flow slipped to $26.0 million in Q1 2026 per SLNO's latest filing, from $48.6 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $48.6 million in Q4 2025 and bottomed at -$32.8 million in Q1 2025.
- Historically, Free Cash Flow has averaged -$2.5 million across 5 years, with a median of -$6.3 million in 2023.
- Annual changes were most pronounced in 2024 — Free Cash Flow slumped 280.09% — and 2025, when it jumped 387.71%.
- Soleno Therapeutics' Free Cash Flow stood at -$5.1 million in 2022, then decreased by 22.94% to -$6.3 million in 2023, then plunged by 280.09% to -$24.0 million in 2024, then jumped by 302.71% to $48.6 million in 2025, then plunged by 46.6% to $26.0 million in 2026.
- Business Quant data shows SLNO's Free Cash Flow at $26.0 million in Q1 2026, $48.6 million in Q4 2025, and $43.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn | 25.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.98 Mn |
| Mar 31, 2026 | 25.98 Mn |
| Dec 31, 2025 | 48.65 Mn |
| Dec 31, 2025 | 48.65 Mn |
| Sep 30, 2025 | 43.49 Mn |
| Sep 30, 2025 | 43.49 Mn |
| Jun 30, 2025 | -12.66 Mn |
| Jun 30, 2025 | -12.66 Mn |
| Mar 31, 2025 | -32.75 Mn |
| Mar 31, 2025 | -32.75 Mn |
| Dec 31, 2024 | -24.00 Mn |
| Dec 31, 2024 | -24.00 Mn |
| Sep 30, 2024 | -15.12 Mn |
| Sep 30, 2024 | -15.12 Mn |
| Jun 30, 2024 | -17.66 Mn |
| Jun 30, 2024 | -17.66 Mn |
| Mar 31, 2024 | -12.54 Mn |
| Mar 31, 2024 | -12.54 Mn |
| Dec 31, 2023 | -6.31 Mn |
| Dec 31, 2023 | -6.31 Mn |